Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

This study has been completed.
Information provided by (Responsible Party):
Association for Innovation and Biomedical Research on Light and Image Identifier:
First received: January 20, 2011
Last updated: March 18, 2015
Last verified: April 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2013
  Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)